文献速递湿疹皮炎与荨麻疹

芦可替尼乳膏治疗皮肤扁平苔藓的随机临床试验

Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2026-09-23

这项2期随机双盲载体对照试验纳入64例中重度皮肤扁平苔藓成人患者,评估1.5%芦可替尼乳膏每日两次治疗16周的疗效与安全性。

要点

  • 1.5%芦可替尼乳膏每日两次可显著改善皮肤扁平苔藓的皮损和瘙痒。
  • 第16周IGA治疗成功率为50.0%,显著高于载体组的21.9%。
  • 芦可替尼乳膏耐受性良好,未观察到严重治疗中出现的不良事件。

核心结论

  • 1.5%芦可替尼乳膏可显著减少皮肤扁平苔藓患者的皮损并改善瘙痒,可能成为潜在治疗选择。

研究设计与样本

  • 共随机64例成人皮肤扁平苔藓患者,1:1分配至1.5%芦可替尼乳膏或载体乳膏每日两次治疗16周。
  • 纳入标准包括IGA评分为3或4、瘙痒NRS评分≥4、受累体表面积≤20%。

主要发现

  • 疗效在开放标签延展期至第32周进一步改善。
  • 芦可替尼乳膏未观察到严重治疗中出现的不良事件或因不良事件停药。

关键数值与推荐

  • 主要终点为第16周IGA治疗成功(IGA评分0或1且较基线改善≥2级)。
  • 次要终点包括第16周瘙痒NRS评分较基线改善≥4分的患者比例。

临床怎么用

  • 对于受累体表面积≤20%、IGA 3或4且瘙痒NRS≥4的皮肤扁平苔藓成人患者,1.5%芦可替尼乳膏每日两次可作为潜在治疗选择。
  • 治疗16周可评估皮损和瘙痒应答,延续治疗至32周可能进一步改善。

局限性

  • 样本量较小(共64例),随访至第32周,长期疗效和安全性需进一步研究。
  • 研究纳入受累体表面积≤20%的患者,结果外推至更广泛人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lichen planus is a chronic, highly pruritic, inflammatory disease that affects the skin and other tissues. OBJECTIVE: To evaluate the efficacy and safety of ruxolitinib, 1.5%, cream in patients with cutaneous lichen planus. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, 16-week, randomized, double-blind, vehicle-controlled trial with a 16-week open-label extension was conducted from November 2022 to February 2024. Patients were enrolled from 19 sites in the US and Canada. The trial included adults with predominantly cutaneous lichen planus, an Investigator's Global Assessment (IGA) score of 3 or 4, an Itch Numerical Rating Scale score of 4 or greater, and an affected body surface area of 20% or less were enrolled. Data were analyzed from February to August 2024. INTERVENTIONS: Patients were randomized 1:1 to ruxolitinib, 1.5%, twice daily cream or vehicle cream for 16 weeks, after which eligible patients applied ruxolitinib cream twice daily as needed in a 16-week, open-label extension. MAIN OUTCOMES AND MEASURES: The primary end point was IGA treatment success (IGA score of 0 or 1 [clear/almost clear skin] with a ≥2-grade improvement from baseline) at week 16. RESULTS: Among 64 randomized patients, 46 (72%) were female, 18 (28%) were male, 18 (28%) were African American/Black, 4 (6%) were Asian, 40 (63%) were White, and the median (range) age was 57.0 (18-78) years. Significantly more patients who applied ruxolitinib, 1.5%, cream vs vehicle achieved IGA treatment success (50.0% [95% CI, 31.9%-68.1%] vs 21.9% [95% CI, 9.3%-40.0%], respectively; response rate difference, 29.4% [95% CI, 7.6%-51.3%]; P = .01; primary end point) at week 16, with further improvement to week 32. Similar results were observed in the proportion of patients who achieved a 4 or greater-point improvement from baseline in Itch Numerical Rating Scale score (week 16, 48.4% [95% CI, 30.2%-66.9%] vs 16.1% [95% CI, 5.5%-33.7%]; response rate difference, 33.5%; 95% CI, 12.2%-54.9%; P = .004; secondary end point). No serious treatment-emergent adverse events or discontinuations due to an adverse event were observed with ruxolitinib cream. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that ruxolitinib cream significantly reduced lesions and itch in patients with lichen planus. Therefore, ruxolitinib cream represents a potential treatment option for patients with cutaneous lichen planus. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05593432.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Mangold AR, Lockshin B, Lai Z, et al. Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial. JAMA Dermatol. 2026. PMID: 42776548. doi:10.1001/jamadermatol.2026.3646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。